Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity causes mouse neonate lethality.

Código QR

Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity causes mouse neonate lethality.

Dipeptidyl Peptidase (DPP) 4 and related dipeptidyl peptidases are emerging as current and potential therapeutic targets. DPP9 is an intracellular protease that is regulated by redox status and by SUMO1. DPP9 can influence antigen processing, epidermal growth factor (EGF)-mediated signaling and tumo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Margaret G Gall, Yiqian Chen, Ana Julia Vieira de Ribeiro, Hui Zhang, Charles G Bailey, Derek S Spielman, Denise M T Yu, Mark D Gorrell
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a53568362b3e4e698b1e39e9eef2c700
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
por: Taras S. Panevin, et al.
Publicado: (2020)

Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose
por: Das SS, et al.
Publicado: (2014)

Dipeptidyl Peptidase-4 and Adolescent Idiopathic Scoliosis: Expression in Osteoblasts
por: Emilie Normand, et al.
Publicado: (2017)

Dipeptidyl peptidase-IV inhibitory action of Calebin A: An in silico and in vitro analysis
por: Nehru Sai Suresh Chalichem, et al.
Publicado: (2021)

Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma
por: James M. Henderson, et al.
Publicado: (2021)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
por: Lin YH, et al.
Publicado: (2019)

Dipeptidyl peptidase 4 promotes peritoneal fibrosis and its inhibitions prevent failure of peritoneal dialysis
por: Yi-Chen Li, et al.
Publicado: (2021)

Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus
por: Gurgel Penaforte-Saboia J, et al.
Publicado: (2021)

The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
por: Aleksander Sergeevich Ametov, et al.
Publicado: (2015)

Molecular Dynamics Simulations Study of the Interactions between Human Dipeptidyl-Peptidase III and Two Substrates
por: Shitao Zhang, et al.
Publicado: (2021)

Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
por: Chen L, et al.
Publicado: (2020)

Gliptins vs. Milk-derived Dipeptidyl-Peptidase IV Inhibiting Biopeptides: Physicochemical Characterization and Pharmacokinetic Profiling
por: Jorge Andrés Barrero, et al.
Publicado: (2021)

Dipeptidyl peptidase III as a DNA marker to investigate epidemiology and taxonomy of Old World Leishmania species.
por: Insaf Bel Hadj Ali, et al.
Publicado: (2021)

Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes
por: Galina Smushkin, et al.
Publicado: (2009)

Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis
por: Lana C. Pinto, et al.
Publicado: (2018)

Structural basis for an exceptionally strong preference for asparagine residue at the S2 subsite of Stenotrophomonas maltophilia dipeptidyl peptidase 7
por: Akihiro Nakamura, et al.
Publicado: (2021)

Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
por: Suman RK, et al.
Publicado: (2016)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han E, et al.
Publicado: (2020)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
por: Lyudmila Viktorovna Nedosugova, et al.
Publicado: (2014)

Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats.
por: Soo Lim, et al.
Publicado: (2012)

Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study
por: Sheriza Baksh, et al.
Publicado: (2021)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
por: Gagik Radikovich Galstyan, et al.
Publicado: (2015)

Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
por: Ming Zhao, et al.
Publicado: (2017)

Plasma dipeptidyl-peptidase-4 activity is associated with left ventricular systolic function in patients with ST-segment elevation myocardial infarction
por: Jing Wei Li, et al.
Publicado: (2017)

The Effect of Bioactive Polyphenols from <i>Anacardium occidentale</i> Linn. Leaves on α-Amylase and Dipeptidyl Peptidase IV Activities
por: Nur Imanina Abdullah Thaidi, et al.
Publicado: (2020)

Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain
por: Kornél Király, et al.
Publicado: (2018)

Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
por: Taehwan Park, et al.
Publicado: (2021)

Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glimepiride
por: Woodman OL, et al.
Publicado: (2019)

Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
por: Wang N, et al.
Publicado: (2019)

Sequential alcalase and flavourzyme treatment for preparation of α-amylase, α-glucosidase, and dipeptidyl peptidase (DPP)-IV inhibitory peptides from oat protein
por: Lourdes Ramírez Fuentes, et al.
Publicado: (2021)

Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
por: Hiroshi Kasamatsu, et al.
Publicado: (2021)

Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review.
por: Martin C S Wong, et al.
Publicado: (2014)

A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction
por: Joanne M. Hildebrand, et al.
Publicado: (2020)

The Role of Kainate Receptors in the Pathophysiology of Hypoxia-Induced Seizures in the Neonatal Mouse
por: Denise K. Grosenbaugh, et al.
Publicado: (2018)

THERAPEUTIC EFFICACY OF MONOCLONAL ANTIBODIES AGAINST LETHAL TOXIN OF BACILLUS ANTHRACIS IN A MOUSE MODEL
por: Ia. O. Muntian, et al.
Publicado: (2018)

Machine learning differentiates enzymatic and non-enzymatic metals in proteins
por: Ryan Feehan, et al.
Publicado: (2021)

Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2
por: Shihui Sun, et al.
Publicado: (2021)

Structures of lipoprotein signal peptidase II from Staphylococcus aureus complexed with antibiotics globomycin and myxovirescin
por: Samir Olatunji, et al.
Publicado: (2020)

Covalent assembly of nanoparticles as a peptidase-degradable platform for molecular MRI
por: Francisco Perez-Balderas, et al.
Publicado: (2017)

Transcriptome-wide identification of novel imprinted genes in neonatal mouse brain.
por: Xu Wang, et al.
Publicado: (2008)